Search | eNauka

Research outputs

Gene polymorphism of folate metabolizing enzymes and susceptibility to lung adenocarcinoma in Serbia [2012]

Janković, Radmila ; Čavić, Milena ; Krivokuća, Ana ; Ksenija Brotto; Mališić, Emina ; Spasić, Jelena ; Radosavljević, Davorin ; Radulović, Siniša

Adjuvant treatment modalities and outcomes in locally advanced rectal cancer with neoadjuvant treatment [2014]

Neda Nikolić; Nikolić, Vladimir ; Davorin Radosavljević; Zorica Tomasević; Nemanja Stanić; Suzana Rundić-Stojanović; Jelena Spasić; Srdjan Nikolić

Persistent prevention of CIPN using calmangafodipir (Pled Ox): Results from a placebo-controlled randomized phase II study (PLIANT) in patients with metastatic colorectal cancer (mCRC). [2016]

Glimelius, Bengt; Manojlović, Nebojša S. ; Pfeiffer, Per; Mosidze, Baadur; Petrova-Kurteva, Galina; Karlberg, Mia; Mahalingam, Devalingam; Bengtson, Marie; Nasstrom, Jacques

Final results from a phase III trial evaluating panitumumab (pmab) plus best supportive care (BSC) vs BSC in chemorefractory wild-type (WT) KRAS exon 2 and WT RAS metastatic colorectal cancer (mCRC). [2016]

Kim, Tae Won; ...; Kusic, Zvonko; ...; Manojlović, Nebojša S. ; ...; (broj, koautora 16)

Association of ECOG performance status with efficacy in patients receiving panitumumab with best supportive care (BSC) vs BSC alone for chemorefractory metastatic colorectal cancer [2016]

Vrdoljak, Eduard; ...; Kusic, Zvonko; ...; Manojlovic, Nebojsa S ; ...; (broj, koautora 16)

Phase II randomized trial of MEK inhibitor pimasertib or placebo combined with gemcitabine in the first-line treatment of metastatic pancreatic cancer. [2015]

Van, Cutsem Eric; Hidalgo, Manuel; Bazin, Igor; Canon, Jean-Luc; Poddubskaya, Elena; Manojlović, Nebojša S ; Milella, Michele; Radenkovic, Dejan V; Verslype, Chris; Guo, Wei;

Damstrup, Lars; Hammel, Pascal;

Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAF(V600)-positive melanoma: Interim analysis of the ImmunoCobiVem study. [2022]

Schadendorf, Dirk; ...; Kandolf-Sekulovic, Lidija O; ...; Mijuskovic, Željko P ; ...; (broj, koautora 20)

A phase II, randomized, double-blind, placebo-controlled trial evaluating efficacy and safety of namodenoson (CF102), an A(3) adenosine receptor agonist (A(3)AR), as a second-line treatment in patients with Child-Pugh B (CPB) advanced hepatocellular carcinoma (HCC). [2019]

Stemmer, Salomon M; Manojlovic, Nebojsa S ; ...; Natosevic, Sladjana; ...; (broj, koautora 20)